Logo image of INFI

INFINITY PHARMACEUTICALS INC (INFI) Stock Analyst Ratings

NASDAQ:INFI - Nasdaq - US45665G3039 - Common Stock - Currency: USD

0.0447  -0.04 (-46.98%)

After market: 0.04 0 (-10.51%)

Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to INFI. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 0.31. This target is 584.56% above the current price.
INFI was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about INFI.
In the previous month the buy percentage consensus was at a similar level.
INFI was analyzed by 6 analysts. More opinions would make the average more meaningful.

Related screens

INFI Historical Analyst RatingsINFI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -81 -73 -65 -57 -49 -41 -33 -25 -17 -9 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.040.300.310.310.32 - 577.85% 584.56% 584.56% 604.70%

Related screens

INFI Current Analyst RatingINFI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2023-02-24 Piper Sandler Downgrade Overweight -> Neutral
2022-11-16 B. Riley Securities Downgrade Buy -> Neutral
2022-05-23 Piper Sandler Maintains Overweight
2021-10-18 HC Wainwright & Co. Initiate Buy
2021-08-02 JP Morgan Upgrade Neutral -> Overweight
2021-07-28 Wells Fargo Upgrade Equal-Weight -> Overweight
2021-03-18 Truist Securities Initiate Buy
2021-03-17 Wells Fargo Maintains Equal-Weight
2021-02-18 Piper Sandler Initiate Overweight